Bill To Revise US Subject Matter Patent Eligibility Standard Expected By 'Early Summer'
Senators emphasize need for legislative reform at IP subcommittee hearing; ask USPTO director Iancu how a drug can have 130 patents, alluding to Humira.
You may also be interested in...
Battle Begins Over Legislation To Expand What Inventions May Be Patented
BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.
US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.